After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...

The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.

The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...

CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

The target of the strike in Lebanon was the group’s leader, Hassan Nasrallah, according to Israeli and American officials. The attack came shortly after the Israeli prime minister gave a defiant ...

Eric Adams Awaits Arraignment in Court on Bribery and Fraud Charges The New York mayor was scheduled to be arraigned today. He has insisted he will stay in office and asked New Yorkers to give him ...

Get the latest Australian and world news covering breaking news and trending topics that educate, engage and entertain. Learn more about where you live, the language you speak, and how the country ...